SCHEMBL30007072

SCHEMBL30007072

CC(C)(O)c1cc(C(O)(CN)C(C)(F)F)nc(-c2ccc(F)cc2)c1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 3/20 0.38
ADORA2A P29274 3/20 0.35
ADORA2B P29275 1/20 0.35
ALDH1A1 P00352 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CNR2 P34972 5/20 0.33
ADORA1 P30542 2/20 0.33
CNR1 P21554 2/20 0.32
CYP3A4 P08684 2/20 0.32
CYP2C9 P11712 2/20 0.32
CYP2C19 P33261 2/20 0.32
KDM4E B2RXH2 2/20 0.32
PTGS2 P35354 1/20 0.32
NPC1 O15118 1/20 0.32
MAPT P10636 1/20 0.32
PKM P14618 1/20 0.32
HPGD P15428 1/20 0.32
MAPK1 P28482 1/20 0.32
RAB9A P51151 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25687150 1.00 CFTR (0.38) CFTRADORA2AADORA2BALDH1A1L3MBTL1
SCHEMBL25687148 1.00 CFTR (0.38) CFTRADORA2AADORA2BALDH1A1L3MBTL1
SCHEMBL23930046 1.00 CFTR (0.38) CFTRADORA2AADORA2BALDH1A1L3MBTL1
SCHEMBL30211264 0.93 CFTR (0.39) CFTRADORA2AALDH1A1L3MBTL1CNR2
SCHEMBL30692531 0.93 CFTR (0.39) CFTRADORA2AALDH1A1L3MBTL1CNR2
SCHEMBL25686591 0.93 CFTR (0.39) CFTRADORA2AALDH1A1L3MBTL1CNR2
SCHEMBL25285421 0.93 CFTR (0.38) CFTRADORA2AALDH1A1L3MBTL1CNR2
SCHEMBL23958625 0.93 CFTR (0.39) CFTRADORA2AALDH1A1L3MBTL1CNR2
SCHEMBL25686593 0.93 CFTR (0.39) CFTRADORA2AALDH1A1L3MBTL1CNR2
SCHEMBL23958981 0.92 ADORA2A (0.32) CFTRADORA2AADORA2BALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
EP-4139293-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2023-03-01 EP disclosed
CN-115461336-A RSV inhibiting 3-substituted quinoline and cinnoline derivatives 爱尔兰詹森科学公司 2022-12-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES ACE2, SIRT7, ACE CFTR 508/4885ADORA2A 3556/4885ADORA2B 2122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.